Hussain Saleem Lalani, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prescription Drugs | 7 | 2024 | 631 | 2.030 |
Why?
|
Politics | 5 | 2024 | 815 | 1.690 |
Why?
|
Drugs, Generic | 6 | 2024 | 448 | 1.670 |
Why?
|
Drug Costs | 7 | 2024 | 1183 | 1.290 |
Why?
|
Medicare Part D | 4 | 2024 | 355 | 1.040 |
Why?
|
Health Expenditures | 5 | 2024 | 2366 | 0.890 |
Why?
|
Physicians | 4 | 2024 | 4591 | 0.880 |
Why?
|
Prescription Fees | 1 | 2024 | 153 | 0.870 |
Why?
|
Glucagon-Like Peptides | 1 | 2024 | 153 | 0.840 |
Why?
|
Negotiating | 1 | 2023 | 150 | 0.810 |
Why?
|
Critical Care | 3 | 2019 | 2697 | 0.780 |
Why?
|
Trust | 1 | 2023 | 530 | 0.600 |
Why?
|
Financing, Government | 1 | 2021 | 472 | 0.580 |
Why?
|
Hospitals, Public | 1 | 2018 | 202 | 0.570 |
Why?
|
Patient Care Management | 1 | 2019 | 302 | 0.540 |
Why?
|
Attitude to Death | 1 | 2019 | 400 | 0.510 |
Why?
|
Information Dissemination | 1 | 2023 | 1126 | 0.470 |
Why?
|
Biological Products | 1 | 2023 | 914 | 0.470 |
Why?
|
Empathy | 1 | 2019 | 473 | 0.460 |
Why?
|
Managed Care Programs | 1 | 2019 | 940 | 0.460 |
Why?
|
Pharmacies | 2 | 2024 | 169 | 0.400 |
Why?
|
Internship and Residency | 2 | 2024 | 5882 | 0.390 |
Why?
|
United States | 16 | 2024 | 72335 | 0.320 |
Why?
|
Patient Acceptance of Health Care | 2 | 2019 | 3205 | 0.310 |
Why?
|
Medicaid | 6 | 2024 | 2818 | 0.310 |
Why?
|
Medicare | 6 | 2024 | 6770 | 0.280 |
Why?
|
Drug Industry | 2 | 2024 | 788 | 0.270 |
Why?
|
Referral and Consultation | 1 | 2018 | 3600 | 0.250 |
Why?
|
Intensive Care Units | 1 | 2018 | 3744 | 0.240 |
Why?
|
Health Personnel | 1 | 2019 | 3335 | 0.240 |
Why?
|
Hospital Mortality | 1 | 2018 | 5293 | 0.240 |
Why?
|
Medical Assistance | 1 | 2024 | 108 | 0.230 |
Why?
|
Palliative Care | 1 | 2019 | 3598 | 0.220 |
Why?
|
Insurance, Pharmaceutical Services | 1 | 2024 | 348 | 0.200 |
Why?
|
Intellectual Property | 1 | 2021 | 31 | 0.190 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2021 | 63 | 0.190 |
Why?
|
Investments | 1 | 2023 | 147 | 0.190 |
Why?
|
Cardiovascular Diseases | 2 | 2024 | 15501 | 0.190 |
Why?
|
Health Services Accessibility | 1 | 2019 | 5440 | 0.180 |
Why?
|
Humans | 26 | 2024 | 761572 | 0.180 |
Why?
|
Eligibility Determination | 1 | 2024 | 421 | 0.180 |
Why?
|
Cost Savings | 2 | 2024 | 913 | 0.180 |
Why?
|
Economic Competition | 1 | 2022 | 219 | 0.170 |
Why?
|
Texas | 1 | 2021 | 404 | 0.170 |
Why?
|
Financing, Organized | 1 | 2021 | 204 | 0.170 |
Why?
|
Insurance Claim Review | 1 | 2024 | 741 | 0.160 |
Why?
|
Gambia | 1 | 2019 | 104 | 0.160 |
Why?
|
Nurse-Patient Relations | 1 | 2019 | 100 | 0.160 |
Why?
|
New York | 1 | 2021 | 874 | 0.150 |
Why?
|
Drug Utilization | 2 | 2021 | 1188 | 0.150 |
Why?
|
Case Management | 1 | 2019 | 272 | 0.140 |
Why?
|
Economics, Hospital | 1 | 2019 | 210 | 0.140 |
Why?
|
California | 1 | 2021 | 1430 | 0.140 |
Why?
|
Cross-Sectional Studies | 5 | 2024 | 26127 | 0.140 |
Why?
|
Africa South of the Sahara | 1 | 2019 | 744 | 0.130 |
Why?
|
Kenya | 1 | 2018 | 758 | 0.130 |
Why?
|
Hepatitis C, Chronic | 1 | 2024 | 1032 | 0.130 |
Why?
|
World Health Organization | 1 | 2021 | 1322 | 0.120 |
Why?
|
Patient Readmission | 2 | 2019 | 3271 | 0.120 |
Why?
|
Aged | 8 | 2024 | 169310 | 0.120 |
Why?
|
Heart Failure | 1 | 2019 | 11670 | 0.120 |
Why?
|
Reimbursement, Incentive | 1 | 2019 | 543 | 0.110 |
Why?
|
Hepatitis C | 1 | 2024 | 1584 | 0.110 |
Why?
|
Anticholesteremic Agents | 1 | 2021 | 966 | 0.110 |
Why?
|
Combined Modality Therapy | 1 | 2023 | 8528 | 0.100 |
Why?
|
Hypoglycemic Agents | 1 | 2024 | 3085 | 0.100 |
Why?
|
Middle Aged | 6 | 2024 | 220920 | 0.090 |
Why?
|
Retrospective Studies | 5 | 2023 | 80646 | 0.080 |
Why?
|
RNA, Messenger | 1 | 2023 | 12794 | 0.070 |
Why?
|
Male | 8 | 2024 | 360842 | 0.070 |
Why?
|
Adult | 5 | 2024 | 221203 | 0.070 |
Why?
|
Survival Analysis | 1 | 2018 | 10090 | 0.060 |
Why?
|
Cuba | 1 | 2024 | 48 | 0.060 |
Why?
|
Female | 7 | 2024 | 392686 | 0.060 |
Why?
|
Longitudinal Studies | 1 | 2019 | 14607 | 0.050 |
Why?
|
Primary Health Care | 1 | 2019 | 4686 | 0.050 |
Why?
|
Hospitalization | 2 | 2019 | 10721 | 0.050 |
Why?
|
State Government | 1 | 2024 | 384 | 0.050 |
Why?
|
Diabetes Mellitus | 1 | 2019 | 5841 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2024 | 12148 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 7879 | 0.040 |
Why?
|
Medical Staff | 1 | 2019 | 40 | 0.040 |
Why?
|
Aged, 80 and over | 2 | 2019 | 58986 | 0.040 |
Why?
|
Hepacivirus | 1 | 2024 | 1336 | 0.030 |
Why?
|
Medically Uninsured | 1 | 2020 | 836 | 0.030 |
Why?
|
Drug Combinations | 1 | 2021 | 2048 | 0.030 |
Why?
|
Risk Reduction Behavior | 1 | 2019 | 1112 | 0.030 |
Why?
|
Young Adult | 1 | 2018 | 59255 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2024 | 3060 | 0.020 |
Why?
|
Cholesterol, LDL | 1 | 2021 | 2382 | 0.020 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2020 | 1188 | 0.020 |
Why?
|
Program Evaluation | 1 | 2019 | 2495 | 0.020 |
Why?
|
Child | 1 | 2018 | 80156 | 0.020 |
Why?
|
Adolescent | 1 | 2018 | 88324 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 3245 | 0.020 |
Why?
|
Public Health | 1 | 2019 | 2669 | 0.020 |
Why?
|
Databases, Factual | 1 | 2021 | 7967 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2019 | 7827 | 0.020 |
Why?
|
Atherosclerosis | 1 | 2021 | 3408 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2019 | 4330 | 0.010 |
Why?
|
Risk Factors | 1 | 2019 | 74213 | 0.010 |
Why?
|